Further studies are needed to confirm or rule out the hypothesis that decreased salivary SOD/GPx activity may be a specific biomarker of AD and help differentiate or assess the severity of the degree or duration of this disease, as is the case with lactoferrin. This evidence concerns the gene LTF and Alzheimer disease.